Figure 3
Hazard ratio and 95% confidence interval of mortality within the first 18-month follow-up period for NSCLC patients who presented with a high pretreatment serum CYFRA 21-1 level (symbols as in Figure 2; P⩽10−4). Results from the Jules Bordet Institute were not presented insofar as the proportional hazard assumption was not verified for these variables during the first 18-month period.
